Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)

• Status: Completed
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the Area Under the Curve (AUC(0 to infinity)) of anacetrapib in subjects with impaired renal function and healthy matched control subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Anacetrapib; Oxazolidinones

Criteria

Inclusion Criteria:

• Female subjects of reproductive potential test negative for pregnancy and agree to use two acceptable methods of birth control throughout the study

• Subject is in good health

• If Subject is a smoker, smoking is limited to no more than 10 cigarettes per day

Exclusion Criteria:

• Subject has a history of stroke, chronic seizures or major neurological disorder

• Subject has a history of cancer

• Subject is unable to refrain from or anticipates the use of any prescription or non-prescription medication during the study

• Subject consumes excessive amounts of alcohol or caffeine

• Subject has had major surgery, donated blood or participated in another investigational study within the past 4 weeks

• Subject is a nursing mother

• Subject has had a kidney removed or has a functioning renal transplant